In December 2025, CITEST Diagnostics launched its comprehensive DOA (Drugs of Abuse) Rapid Test Range, offering a complete portfolio of solutions for both urine and surface specimen detection. These tests provide a reliable choice for professionals, enabling the qualitative detection of a wide spectrum of substances from common drugs to novel synthetic compounds. With their high accuracy and flexible formats, these rapid tests serve as an indispensable tool for preliminary screening in various settings.
These rapid test kits stand out with their operational convenience and reliable performance. Designed as user-friendly devices, they feature straightforward procedures with simple visual interpretation and deliver fast results. The flexible formats, including dipsticks, cassettes and panels, cater to diverse testing needs and workflows, combining versatility with efficiency in the drug screening process.
The range offers four core advantages: it provides high accuracy in detection, ensuring reliable presumptive results; it features an easy visual interpretation system, minimizing reading errors; it delivers fast and reliable results to support timely decision-making; and it offers multiple format flexibility, from individual tests to multi-analyte panels, to suit different operational requirements. Product offerings are comprehensive, covering urine specimens for drugs like Aripiprazole, Diphenoxylate, Dextromethorphan and Nitazene, as well as surface tests for forensic applications targeting substances including AB-PINACA, Amphetamine, Fentanyl and Cocaine, available in various pack sizes.
In conclusion, Citest's DOA Rapid Test Range redefines professional drug screening by integrating a comprehensive detection panel, user-friendly operation, reliable results and format flexibility. By addressing the critical need for efficient and accurate preliminary substance identification, these tests empower professionals in healthcare, workplace safety and forensic investigations with actionable insights. Citest Diagnostics remains committed to developing innovative, accessible diagnostic solutions that enhance safety protocols and support informed decision-making globally.
